Savara (NASDAQ:SVRA) Hits New 52-Week Low After Analyst Downgrade

Savara Inc (NASDAQ:SVRA) shares reached a new 52-week low during mid-day trading on Thursday after HC Wainwright lowered their price target on the stock from $10.00 to $6.00. HC Wainwright currently has a buy rating on the stock. Savara traded as low as $3.24 and last traded at $3.32, with a volume of 128515 shares trading hands. The stock had previously closed at $3.25.

SVRA has been the subject of a number of other reports. Evercore ISI restated an “in-line” rating and set a $5.00 price objective (down from $7.00) on shares of Savara in a research report on Wednesday. JMP Securities restated a “market outperform” rating and set a $9.00 price objective on shares of Savara in a research report on Tuesday, October 1st. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $10.17.

Institutional Investors Weigh In On Savara

Large investors have recently modified their holdings of the business. CANADA LIFE ASSURANCE Co purchased a new stake in shares of Savara during the first quarter worth $35,000. Choreo LLC purchased a new stake in shares of Savara during the second quarter worth $59,000. DRW Securities LLC purchased a new stake in shares of Savara during the second quarter worth $62,000. Principal Financial Group Inc. grew its holdings in shares of Savara by 64.4% during the second quarter. Principal Financial Group Inc. now owns 17,795 shares of the company’s stock worth $72,000 after buying an additional 6,973 shares in the last quarter. Finally, BNP Paribas Financial Markets grew its holdings in shares of Savara by 258.9% in the third quarter. BNP Paribas Financial Markets now owns 25,693 shares of the company’s stock valued at $109,000 after purchasing an additional 18,534 shares during the period. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Savara Price Performance

The company has a debt-to-equity ratio of 0.26, a current ratio of 11.31 and a quick ratio of 11.31. The stock’s fifty day moving average is $3.93 and its 200-day moving average is $4.21. The stock has a market cap of $525.08 million, a PE ratio of -7.60 and a beta of 1.02.

Savara (NASDAQ:SVRA) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.11) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.11). As a group, equities analysts anticipate that Savara Inc will post -0.44 EPS for the current year.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.